The ATRN Knockout A-549 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal population derived from the human A-549 lung adenocarcinoma cell line, with targeted disruption of the ATRN gene encoding attractin. This polyclonal knockout pool eliminates attractin function, providing a robust loss-of-function model to investigate melanocortin signaling and cell adhesion. The heterogeneous nature of the polyclonal cells minimizes clonal artifacts and better represents genetic variability. The cells are generated through CRISPR/Cas9-mediated gene disruption without single-cell cloning, ensuring a reproducible and versatile research tool.
The A-549 cell line is a widely used human lung adenocarcinoma model established from the explanted lung tumor tissue of a 58-year-old Caucasian male. Characterized as alveolar basal epithelial cells, A-549 cells are adherent and exhibit key features of lung adenocarcinoma, making them ideal for cancer biology, drug screening, and tumor microenvironment studies. This background offers a clinically relevant platform to explore the intersection of ATRN function with oncogenic processes and immune interactions.
Attractin, encoded by ATRN, is a transmembrane receptor for agouti-related protein (AgRP) and participates in melanocortin receptor modulation. It facilitates AgRP antagonism of ??-MSH at melanocortin receptors MC1R and MC4R, influencing adenylate cyclase/cAMP/PKA signaling. Downstream, this pathway regulates CREB phosphorylation and can affect tyrosinase expression and ICAM-1-mediated adhesion. ATRN also mediates homophilic cell adhesion. Knockout of ATRN disrupts AgRP binding and melanocortin receptor crosstalk, leading to altered cAMP/PKA signaling and impaired adhesion, which may impact immune cell interactions and metabolic regulation.
In A-549 lung adenocarcinoma cells, loss of ATRN has profound implications for understanding the role of melanocortin signaling and immune cell adhesion in cancer. Although these cells are non-pigmented, attractin??s adhesion functions and its modulation of inflammatory responses suggest that ATRN knockout may alter tumor-immune crosstalk, potentially affecting immune evasion or cytokine-driven inflammation. Moreover, coupling with metabolic pathways via AgRP makes this model relevant for studying how energy homeostasis intersects with cancer metabolism in lung adenocarcinoma.
This polyclonal knockout cell pool supports diverse experimental approaches, including cAMP assays, RT-qPCR for POMC and MC1R, and Western blotting for ATRN and phospho-CREB. Functional studies can employ cell adhesion assays, flow cytometry for MC1R expression, and co-immunoprecipitation of AgRP complexes. Additionally, RNA-seq, migration assays, and pharmacological tests with ??-MSH or AgRP are applicable. Overall, the model facilitates research into obesity, metabolic syndrome, immune dysregulation, and drug discovery targeting attractin interactions. For further information, contact Ascent Research.
